Cargando…

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ning, Yang‐Min, Maher, V. Ellen, Beaver, Julia A., Goldberg, Kirsten B., Blumenthal, Gideon M., Pazdur, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813751/ https://www.ncbi.nlm.nih.gov/pubmed/29180460 http://dx.doi.org/10.1634/theoncologist.2017-0415

Ejemplares similares

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

Urothelial Carcinoma
por: Chow, Nan-Haw, et al.
Publicado: (2012)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
por: Dietrich, Brian, et al.
Publicado: (2018)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
por: Okuyama, Yoshiharu, et al.
Publicado: (2021)

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
por: Koshkin, Vadim S., et al.
Publicado: (2019)

Advanced Science – Top Science with Maximum Accessibility
por: Severing, Kirsten
Publicado: (2014)

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
por: Kitamura, Hiroshi, et al.
Publicado: (2011)

Immunotherapy in urothelial carcinoma: fade or future standard?
por: Breyer, Johannes, et al.
Publicado: (2016)

Management of Upper Tract Urothelial Carcinoma
por: Smith, Norm D.
Publicado: (2009)

Emerging diagnostic and therapeutic strategies for urothelial carcinoma
por: Moschini, Marco, et al.
Publicado: (2021)

Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma
por: Zhang, Yueming, et al.
Publicado: (2021)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
por: Chiang, Ryan S, et al.
Publicado: (2022)

Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
por: Anraku, Tsutomu, et al.
Publicado: (2023)

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
por: Beaver, Julia A., et al.
Publicado: (2018)

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
por: Larkins, Erin, et al.
Publicado: (2017)

Chronic Kidney Disease and Upper Tract Urothelial Carcinomas
por: Wang, Li-Jen, et al.
Publicado: (2014)

Building bridges in urothelial carcinoma to face common challenges
por: Mathieu, Romain, et al.
Publicado: (2016)

Are all metachronous multifocal urothelial carcinoma created equal?
por: Reis, Leonardo O.
Publicado: (2018)

Laparoscopic nephroureterectomy for upper tract urothelial carcinoma – Update
por: Lin, Victor C., et al.
Publicado: (2016)

Trimodality therapy in variant urothelial carcinoma: choose wisely
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2017)

Optimizing frontline therapy in advanced urothelial cancer
por: Kwon, Whi-An, et al.
Publicado: (2020)

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
por: Xu, James Xunhai, et al.
Publicado: (2017)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

Introducing Immunotherapy Advances
por: Elliott, Tim
Publicado: (2020)

Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
por: Yang, Huang-Yu, et al.
Publicado: (2019)

Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
por: Hong, Shuo, et al.
Publicado: (2021)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Clinical registries in upper tract urothelial carcinoma: commitment to collaboration
por: Zeng, Jiping, et al.
Publicado: (2023)

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
por: Zichi, Clizia, et al.
Publicado: (2017)

Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy
por: Baek, Seung-Woo, et al.
Publicado: (2020)

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer
por: Miura, Yuki, et al.
Publicado: (2021)

Recent advances in cancer immunotherapy
por: Sun, Weijing
Publicado: (2017)

Recent Advances in Cancer Immunotherapy
por: Suda, Kenichi
Publicado: (2021)

Immunotherapy advances: One year on
por: Elliott, Tim
Publicado: (2022)

Advances in Stem Cell Immunotherapy
por: Anderson, Johnathon D
Publicado: (2023)

Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma
por: Boot, Arnoud, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gm130ah3ranjps6f9v87b6s1c8